Literature DB >> 6402287

The use of intravenous phenylalanine mustard followed by supervoltage irradiation in the treatment of carcinoma of the ovary.

J E Nevin, G Pinzon, T J Baggerly, F G Turner, J J Marsella.   

Abstract

Between 1970 and 1980, 50 patients with carcinoma of the ovary were treated sequentially with six courses of IV phenylalanine mustard (L-PAM), second look surgery, and radiotherapy using the strip technique. Seven patients had advanced Stage I disease and six patients had Stage II disease; all of these patients are alive and well with no evidence of disease (NED) with a mean survival of five years. Thirty-seven patients had Stage III disease: ten of these patients did not respond to L-PAM (26%); 17 patients had a partial response (48%), and four of these (22%) are alive with NED and a mean survival of five years; ten patients (26%) had a complete response to L-PAM and all are alive and well with a mean survival of five years. The presence of a minimal tumor burden after the initial surgery, a mixed histology, a low-grade differentiation, suppression of leukocyte count to below 2000/mm3 after the first course of chemotherapy, and a complete response to L-PAM, were all factors that contributed to the probability of a long-term survival. Tumors responding to L-PAM and then recurring also responded to a combination of cisplatin and adriamycin, and hexamethylmelamine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402287     DOI: 10.1002/1097-0142(19830401)51:7<1273::aid-cncr2820510717>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Whole-abdomen radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy, and second-look laparotomy.

Authors:  R Greiner; A Goldhirsch; B W Davis; E Dreher; T Peyer; G Locher; H Neuenschwander; R Joss; K Brunner; P Veraguth
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 2.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.